Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014
“We look forward to sharing the first clinical data from our AG-120
Phase 1 trial in patients with advanced hematologic malignancies during
the late-breaker session at EORTC-NCI-AACR,” said
Title: Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies.
Presentation time:
Session title: Plenary Session 2: Proffered Paper Session
Abstract Code: 1LBA
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding Agios’ expectations
and beliefs about the potential of IDH1 as a therapeutic target and its
plans and strategies. The words “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and
similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Such statements are subject to numerous important factors, risks
and uncertainties that may cause actual events or results to differ
materially from Agios’ current expectations and beliefs, including risks
and uncertainties relating to: Agios’ ability to successfully commence
and complete necessary preclinical and clinical development of its
product candidates; Agios’ results of clinical trials and preclinical
studies, including subsequent analysis of existing data and new data
received from ongoing and future studies; Agios’ ability to maintain its
collaboration with third parties on acceptable terms; the content and
timing of decisions made by the U.S.
Source:
Agios Pharmaceuticals, Inc.
Lora Pike, 617-649-8608
lora.pike@agios.com